US20130142874A1

US20130142874A1 - Pharmaceutical compositions based on diclofenac

Info

Publication number: US20130142874A1
Application number: US13/481,478
Authority: US
Inventors: Alberto Reiner; Giorgio Reiner
Original assignee: APR Applied Pharma Research SA
Current assignee: APR Applied Pharma Research SA
Priority date: 1996-05-17
Filing date: 2012-05-25
Publication date: 2013-06-06
Also published as: US7482377B2; US20050147671A1; US20050214363A1; US20050215643A1; US6974595B1

Abstract

New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher C_maxof the active principle and shorter T_maxtogether with a lower coefficient of variation.

Description

The present application is a continuation of U.S. Ser. No. 09/524,747, filed Mar. 14, 2000 (pending), which is a continuation in part of U.S. Ser. No. 09/192,493, filed Nov. 17, 1998 (abandoned).
The present invention relates to new immediate release pharmaceutical compositions containing [(2,6-dichloro-anilino)-2-phenyl]-2-acetic acid (more commonly known as Diclofenac) in acid and/or salt form
Diclofenac is a non-steroidal drug which was invented at the end of the sixties by A. Sallmann and R. Pfister (NL-6,604,752 and U.S. Pat. No. 3,558,690 both to Ciba-Geigy) and whose structural formula is indicated below.
Diclofenac is widely dispensed and used owing to its well-known analgesic, anti-pyretic, anti-arthritic, anti-phlogistic and anti-rheumatic properties and it is generally taken orally in the form of normal tablets or tablets covered with coatings resistant to gastric juices, or rectally, or by injection, or topically.
The possibility of taking it in the form of sweets, tablets dissolving in the mouth, drages, chewing gum or other similar pharmaceutical forms or in formulations for the extemporary preparation of Diclofenac-based aqueous solutions and/or suspensions would represent a different mode of administration which is definitely more suitable, especially for children and elderly persons.
Owing to its poor solubility in water, Diclofenac is normally used in salt form; the salts of Diclofenac customarily used are those of sodium, potassium or other alkali and alkaline earth metals, together with salts of organic nature, such as the salts of basic amino acids, such as lysine, arginine and omithine, or other pharmacologically acceptable organic bases which have the ability to render the resulting salt soluble in water.
The pharmaceutical compositions of the Diclofenac salts for oral use are generally 25 accompanied by side effects of not inconsiderable consequence: Diclofenac salts are in fact characterised by a particularly unpleasant and bitter taste and by the fact that they produce a sensation of strong astringency and cause an especially intense form of irritation in the buccal cavity, especially in the area of the larynx.
Although the first problem has been partly solved by using flavourings which are able in some manner to mask the taste, satisfactory solutions have still not been proposed for the two remaining problems.
Therefore, the pharmaceutical compositions containing Diclofenac salts still have a poor palatability which limits their adoption and possible fields of application, despite the excellent therapeutic effect with which they are associated.
A second problem connected to Diclofenac is that, when it is orally administered by means of immediate release formulations, the corresponding T_max(the time to the maximum plasma concentration) is usually located at about 1 hour since administration, this being of course a not completely satisfactory result when a prompt and strong analgesic/anti-pyretic effect is sought for. Furthermore, the corresponding coefficient of variation is normally in the range of 70-90%, which means that the T_maxis strongly variable and dependent on the physical characteristics of the patient (Physicians' Desk Reference, 52 edition, 1998, pag. 1831). Attempts are therefore still being made in order to enhance the rate of absorption of Diclofenac and to provide an earlier onset of the therapeutical effect (N. Davies, K. Anderson; Clinical Pharmacokinetic of Diclofenac, Clin. Pharmacokinet., 1997, Sept. 33(3).
The object of the present invention is therefore that of providing a fully palatable formulation of Diclofenac which is able to generate a more rapid, uniform and foreseeable release of the active principle if compared to the compositions known in the art and presently available on the market. For the purposes of the present invention T_maxmeans the time to the maximum plasma concentration whereas C_maxis the maximum plasma concentration of the active principle, namely Diclofenac. It has now been found that, by adding alkali metal bicarbonates or mixtures thereof to the Diclofenac in its acid and/or salt form, in amounts of from 20 to 80% by weight based on the acid-form of Diclofenac, pharmaceutical compositions can be obtained which are substantially free from the side effects mentioned above. The first object of the present invention is therefore represented by a pharmaceutical formulation for oral use containing Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof and customary excipients and adjuvants, wherein said alkali metal bicarbonates are present in amounts of from 20 to 80% by weight based on the weight of Diclofenac. It has in fact been surprisingly demonstrated that the use of alkali metal bicarbonates in the above-mentioned ratio permits to achieve constant, reproducible and foreseeable blood levels of the active ingredient, with the consequent indisputable advantages from the therapeutic point of view; furthermore, it has also been found that the combined use of Diclofenac together with alkali metal bicarbonates yields Diclofenac-based pharmaceutical compositions in which the active ingredient is released more rapidly compared with normal formulations, bringing about higher blood levels and therefore a more immediate therapeutic effect; finally the so-obtained immediate release formulations are substantially palatable and free from aftertaste.
According to the preferred embodiment of the present invention, the amount of alkali metal bicarbonates to be added is comprised between 40 and 80% by weight, based on the weight of the acid-form Diclofenac, whereas the alkali metal bicarbonates are selected from sodium and/or potassium bicarbonates, Diclofenac being normally present in the form of its sodium and/or potassium salts.
It has also been found, and forms a second subject of the present invention, that the addition of flavouring substances selected from mint, aniseed, ammonium glycyrrhizinate and mixtures thereof to the compositions containing the Diclofenac salts and alkali metal bicarbonates produces, a synergistic effect which completely eliminates all the above-mentioned palatability/astringency effects, providing pharmaceutical compositions which are entirely palatable (and/or drinkable in the case of those used for the preparation of solutions and/or suspensions) and free from aftertaste.
The flavouring substances may be used as such or supported on inert materials, for example maltodextrin, in order to obtain a better distribution of the granulates and to facilitate excellent dispersibility of the flavouring in solution. Preferably, they are absorbed on maltodextrin with a power of 1 to 2000 and 1 to 1000.
The amount of flavouring substances in its pure form is also preferably from ⅕ to 3 times the weight of the acid-form Diclofenac.
These flavouring substances are used in the implementation of the present invention without altering their organoleptic properties and without depriving them of their intrinsic qualities of flavourings which are liposoluble and generally oily in the pure state.

DESCRIPTION OF THE FIGURES

FIG. 1 provides a graph of the average blood level value over time of potassium diclofenac from Formulation A (Ciba-Geigy Voltaren Rapid® tablet form) in the 6 volunteers.

FIG. 2 provides a graph of the average blood level value over time of potassium diclofenac from Formulation B (Ciba-Geigy second comparative formulation) in the 6 volunteers.

FIG. 3 provides a graph of the average blood level value over time of potassium diclofenac from Formulation C (composition of Example 1) in the 6 volunteers.

FIG. 4 provides a comparative graph of the average blood level value over time of potassium diclofenac from the respective Formulations A, B and C in the 6 volunteers.

FIG. 5 provides mean, overlaid plasma concentration-time curves measured in all volunteers after administration of diclofenac test and reference formulations.

FIG. 6 provides mean, overlaid plasma concentration-time profiles measured in all volunteers after administration of diclofenac T₁, T₂, R₁(Cataflam®) and R₂(Voltarol®) formulations.

FIG. 7 provides a mean plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of T₁formulation.

FIG. 8 provides a mean plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of T₂formulation.

FIG. 9 provides a mean plasma concentration-time profile of diclofenac measured in all volunteers after oral administration of R (Voltarene Rapide®) formulation, in linear scale.

FIG. 10 provides mean, overlaid plasma concentration-time profiles measured in all volunteers after administration of diclofenac T₁, T₂, and R (Voltarene Rapide®) formulations.

As it will be clear from the examples, the immediate release formulations for oral use of the present invention containing from 10 to 60 mg of Diclofenac in acid and/or salt form together with alkali metal bicarbonates or mixtures thereof in amounts of from 20 to 80% by weight based on the weight of Diclofenac permit to generate in human patients an average C_maxof Diclofenac comprised between 400 and 2500 ng/ml independently on the age, sex or weight of the patients themselves.
Secondly, the formulations according to the present invention permit to obtain in humans an average T_maxof Diclofenac after 5÷30 minutes since administration, generally 13÷27, independently on the amount of Diclofenac contained therein and also independently on the age, sex, weight of the patient.
Furthermore, the T_maxof the formulations of the present invention show a coefficient of variation which is about 44-86% lower than the presently marketed formulations; this is evidently an extremely important result from the clinical point of view as it is now possible to have a therapeutical effect of Diclofenac which is foreseable, reproducible and independent on the sex, weight and health conditions of the patient.
Thus, the presently claimed Diclofenac-based formulations permit to achieve a higher C_maxin a shorter T_maxand with a lower corfficient of variation if compared to the formulations available on the market, with therapeutical advantages which do not need to be commented.
According to the best mode for carrying out the present invention the pharmaceutical formulations will contain from 10 to 60 mg/dose of diclofenac in its potassium or sodium salt form together with 40 to 80% by weight of potassium or sodium bicarbonate based on the weight of Diclofenac in its acid form, together with the usual excipients and adjuvants; even more preferably they will packaged as:

- a sachet or tablet formulation containing 50 mg of Diclofenac potassium salt and 22 mg of potassium bicarbonate or 50 mg of Diclofenac sodium salt and 19 mg of sodium bicarbonate;
- a sachet or tablet formulation containing 12.5 mg of Diclofenac sodium salt and 5.5 mg of potassium bicarbonate or 25 mg of Diclofenac sodium salt and 11 mg potassium bicarbonate.

It will be by the way evident to any skilled in this art that the present formulations can also be used as immediate release layers of multilayered release pharmaceutical formulations containing Diclofenac as one of the active ingredients; said formulations are therefore a further object of the present invention.
The following Examples are given purely by way of non-limiting illustration.

EXAMPLE 1

Composition Dissolving Instantly in Water


Active ingredients
1) Diclofenac potassium salt*:	50	mg
2) Potassium bicarbonate:	22	mg
3) Mint flavouring on maltodextrin (1:2000)**:	60	mg
4) Aniseed flavouring on maltodextrin (1:1000)***:	104	mg
Excipients and adjuvants
5) Saccharin:	4	mg
6) Aspartame:	10	mg
7) Mannitol:	50	mg
8) Saccharose*** *q.s.:	2	g

*If it is desired to prepare compositions based on Diclofenac sodium salt, it is advantageous to use sodium bicarbonate in a quantity of approximately 38% by weight based on the weight of the Diclofenac sodium salt present. Sodium carbonate may also be added to the sodium bicarbonate, maintaining the following optimum proportions: 27% of sodium bicarbonate and 4-5% of sodium carbonate, always based on the amount by weight of Diclofenac sodium salt present.
**The title of the pure mint essence, as obtained according to the Dean-Stark method, is of 18% by weight; the related amount is therefore in this case of 10.8 mg.
***The title of the pure anise essence, as obtained according to the Dean-Stark method, is of 14.5% by weight, the related amount is therefore in this case of 16 mg.
****The presence of saccharose is not strictly necessary; in its absence, a composition having a very limited granulate content is obtained which is perfectly soluble in contact with water. In that case, nothing is changed from the point of view of tolerability in contact with the mucosa and from the point of view of the palatability of the drinkable solution.

Preparation
Components 1, 2, 5, 6 and 7 are mixed in a suitable mixer, and the mixture so obtained is wetted with 95% ethanol. Granulation is carried out with a 66 mm mesh and the granulate is preferably dried in a current of air.
Components 3, 4 and 8, which have already been granulated using a mesh of the same granulometry, are then added and the whole is mixed.
The mixture is then introduced into a metering machine filing packets or similar containers.

EXAMPLE 2

Tablet for Dissolving in the Mouth


	Active ingredients
	1) Diclofenac potassium salt*:	50 mg
	2) Potassium bicarbonate:	35 mg
	3) Mint flavouring on maltodextrin**	50 mg
	(1:2000) + gum arabic (E 414):
	4) Aniseed flavouring (1:1000)	120 mg
	on maltodextrin*** + silicon
	dioxide (E 551):
	Excipients and adjuvants
	5) Saccharin:	50 mg
	6) Aspartame:	12 mg
	7) Mannitol:	20 mg
	8) Saccharose****:	300 mg

	* to **** see Example 1

Example 3

Gum Tablet


Active ingredients
1) Diclofenac potassium salt*:	50	mg
2) Potassium bicarbonate:	35	mg
3) Mint flavouring on maltodextrin**:	30	mg
4) Aniseed flavouring on maltodextrin***:	80	mg
Excipients and adjuvants
5) Mannitol:	30	mg
6) Menthol:	0.01	mg
7) Gum base:	600	mg
8) Sorbitol:	700	mg
9) Saccharin:	3	mg
10) Hydroxypropylmethylcellulose:	33	mg
11) Colouring agent:	7	mg

to** see Example 1

EXAMPLE 4

Comparative Test

The packaged composition containing 50 mg of Diclofenac potassium of Example 1 (formulation C) was subjected to a pharmacokinetic test for comparison with a similar composition not containing alkali metal carbonates and bicarbonates (formulation B), and with a second composition in tablet form (formulation A) produced by Ciba-Geigy (Voltaren Rapid®), also in this case not containing alkali to metal carbonates and bicarbonates, both formulations A and B containing 50 mg of Diclofenac potassium.
This comparative evaluation was carried out on the same 6 healthy volunteers in accordance with the experimental plan described hereinafter.

- Experimental scheme: Single-dose study using three methods in randomised cross-over with a wash-out of three days.
- Sampling times: 0 h (before administration), 5 min, 10 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, after each administration.
- Blood sample treatment: 8 MI in heparinised test tubes, centrifugation for 15 min at 1500 rev/min, subdivided into two fractions and subsequently frozen at −20° C.
- Times: wash-out of two days between treatments.
- Determination method: HPLC, with internal standard, sensitivity 10 ng/mL

Analysis Method

- Column: Nova Pak C18, 3.9×150 mm, 4 μm Waters S.p.A.—Vimodrone, Italy.
- Eluant: NaH2PO4 0.01 M+0.1% TEA, pH 3.0 (H3PO4)/acetonitrile, 60/40.
- Flow: 1.2 ml/min
- Detection: UV/275 nm
- Temperature: 30° C.
- Injection: 50 al
- Analysis time: 16 min.

Sample Preparation
10 al of the internal standard methanolic solution, and flufenamic acid (corresponding to 1320 ng) are added to 1 ml of defrosted plasma in 10 ml glass test tubes. The tubes are agitated in a Vortex mixer for 1 minute. 0.5 ml of a 0.5N HCl/1N NaCl solution is added. The whole is agitated in a Vortex mixer for 1 minute. 6 ml of a 95/5 n-hexane/isopropanol solution are added.
The mixture is then agitated in the Vortex mixer for a further 15 minutes. Centrifugation is carried out at 3000 rev/min for 15 minutes and the organic phase is transferred to fresh 10 ml glass test tubes and evaporated to dryness in a centrifugal evaporator under vacuum at ambient temperature. The whole is taken up in 200 al of a 70/30 acetonitrile/water solution, and the precipitate is dissolved under ultrasound for 2 minutes.
FIGS. 1, 2 and 3 show the concentrations of Diclofenac in the blood of the six volunteers as regards formulations A, B (Ciba-Geigy comparative formulations) and C (formulation corresponding to the composition of Example 1), respectively. As will be appreciated, the blood concentration of the formulation of the present invention has, compared with the comparative formulations, a more constant and uniform pattern. This characteristic is also found in FIGS. 4, 5 and 6 which show the average values corresponding to the blood levels of the six volunteers together with the corresponding standard deviation.
The result is clear and surprising: compared with the sample compositions, the compositions of the present invention permit constant, reproducible and foreseeable blood levels of the active ingredient, irrespective of the characteristics of the volunteer (weight, age, etc), with the consequent indisputable advantages from the therapeutic point of view.
Finally, FIG. 7 shows, by comparison, the graphs relating to the average values of the six volunteers (that is to say, the preceding FIGS. 4, 5 and 6); as will be noted, the formulation of the present invention permits, in addition to the advantages already mentioned, the attainment of a blood peak higher than that of the other formulations.

EXAMPLE 5

Two Layered Tablet (Fast and Slow Release)


Fast release layer
1) Diclofenac potassium salt:	15	mg
2) Potassium bicarbonate:	30	mg
3) Lactose:	13.2	mg
4) Maize starch (intragranular):	6	mg
5) Methyl cellulose:	0.12	mg
6) Sodium laurylsulfate:	0.06	mg
7) Maize starch (extragranular):	9	mg
8) Crospovidone:	0.6	mg
9) Sodium carboxtmethylstarch:	1.5	mg
10) Magnesium stearate:	2.7	mg
11) Colloidal silicon dioxide:	0.6	mg
Slow release layer
1) Diclofenac potassium salt:	70	mg
2) Potassium bicarbonate:	30.8	mg
3) Lactose:	32.2	mg
4) Polyvinylpyrrolidone:	1.16	mg
5) Hydrpxypropylmethylcellulose:	70	mg
6) Magnesium stearate:	0.84	mg
7) Colloidal silicon dioxide:	0.21	mg
8) Talc:	3.92	mg
9) Polyethylene glycol:	0.56	mg

EXAMPLE 6

Drops


1) Diclofenac potassium salt:	75	g
2) Methyl p-oxybenzoate:	2.7	g
3) Propyl p-oxybenzoate:	0.3	g
4) Aspartame:	37.5	g
5) Potassium bicarbonate:	37.5	g
6) Glycerol:	300	g
7) Ethyl alcool:	450	g
8) Water q.s.:	1500	g

Possible modifications:
a) Addition of sodium metabisulfite (0.06%)
b) Addition of sodium metabisulfite (0.06%)
Mint flavouring (1.25%)
Strawberry flavouring (0.75%)

EXAMPLE 7

Drops


1) Diclofenac potassium salt:	37.5	g
2) Methyl p-oxybenzoate:	2.7	g
3) Propyl p-oxybenzoate:	0.3	g
4) Aspartame:	37.5	g
5) Potassium bicarbonate:	18.75	g
6) Saccharin:	6.0	g
7) Glycerol:	300	g
8) Ethyl alcool:	450	g
9) Water q.s.:	1500	g

Possible modifications:
a) Addition of sodium metabisulfite (0.03%)
b) Addition of sodium metabisulfite (0.03%)
Mint flavouring (1.25%)
Strawberry flavouring (0.75%)

EXAMPLE 8

Mouthwash


1) Diclofenac potassium salt:	0.75	g
2) Glycerol:	50	g
3) Sorbitol:	12	g
4) Saccharin:	0.5	g
5) Aspartame:	1.0	g
6) Methyl p-oxybenzoate:	0.5	g
7) Propyl p-oxybenzoate:	0.1	g
8) Mint flavouring:	1.0	g
9) Ethyl alcool:	100	g
10) Potassium bicarbonate:	0.33	g
11) Water q.s.:	500	ml

EXAMPLE 9

Gum-Paste


1) Diclofenac potassium salt:	5.0	g
2) Glycerol:	630	g
3) Sodium benzoate:	5.0	g
4) Silica (Wessalon S ® - Degussa):	120	g
5) Silica (Siddent 9 ® - Degussa):	80	g
6) Cellulose gum:	3.0	g
7) Polyethylenglycol 600:	30	g
8) Sodium lauroyl sarcosinate (or sodium lauryl sulfate):	60	g
9) Mint flavouring:	10	g
10) Sodium saccharin:	1.0	g
11) Aspartame:	3.0	g
12) Potassium bicarbonate:	2.2	g
13) Water q.s.:	1	kg

EXAMPLE 10

Tooth-Paste


1) Diclofenac potassium salt:	5.0	g
2) Glycerol:	630	g
3) Sodium benzoate:	5.0	g
4) Silica (Wessalon S ® - Degussa):	20	g
5) Silica (Siddent 9 ® - Degussa):	80	g
6) Cellulose gum:	3.0	g
7) Polyethylenglycol 600:	30	g
8) Sodium lauroyl sarcosinate (or sodium lauryl sulfate):	60	g
9) Mint flavouring:	10	g
10) Sodium saccharin:	1.0	g
11) Aspartame:	3.0	g
12) NaF:	1.0	g
13) Na₂FPO₃:	4.0	g
14) Potassium bicarbonate:	2.2	g
15) Water q.s.:	1	kg

EXAMPLE 11

Tablet


	1) Diclofenac potassium salt:	50 mg
	2) Mannitol:	50 mg
	3) Potassium bicarbonate:	22 mg
	4) Maize starch (intragranular):	10 mg
	5) Methyl cellulose:	0.2 mg
	6) Sodium laurylsulfate:	0.1 mg
	7) Maize starch (extragranular):	15 mg
	8) Crospovidone:	1.0 mg
	9) Sodium carboxymethylstarch:	2.5 mg
	10) Magnesium stearate:	4.5 mg
	11) Colloidal silicon dioxide:	10 mg

EXAMPLE 12

Comparative Test

In the present experiment a sachet formulation containing 50 mg of Diclofenac potassium was compared to a bioequivalent sugar coated fast release tablet also containing 50 mg of Diclofenac potassium, produced and marketed in Italy by Novartis as Cataflam®.
The sachet formulation according to the present invention had the following composition:


1) Diclofenac potassium salt:	50	mg
2) Potassium bicarbonate:	22	mg
3) Mint flavour:	50	mg
4) Anice flavour	100	mg
5) Saccharin sodium:	4	mg
6) Aspartame:	10	mg
7) Mannitol:	50	mg
8) Sucrose sugar crystals:	1714	g

The above test formulation and the Cataflam® formulation were administered as a single dose to 24 healthy volunteers of both sexes. The pharmacokinetic parameters obtained with the two different formulations are reported in table 1 and in FIG. 5. As it will be easily appreciated, the rate of absorption was considerably faster with the sachet formulation of the present invention than with Cataflam®, the sachet formulation having a higher average C_max(2213 vs 1071 ng/ml) and a shorter average T_max(0.228 vs 0.885 hours); furthermore, the T_maxof the sachet formulation shows a coefficient of variation lower than the reference formulation (16% vs 97%), this being an extremely important result from the clinical point of view regarding the healing of the pain in terms of quick time and repeteability inter-subjects in order to reach the

EXAMPLE 13

Comparative Test

Following to the excellent results obtained in example 12, two tablet formulations containing 12.5 or 25 mg of Diclofenac sodium salt and potassium bicarbonate (in the same weight ratio) have been prepared.
The tablet formulations had the following composition (in mg):


Cores
Diclofenac sodium	12.5	25
Mannitol	25	50
Lactose monohydrate	23.75	47.5
Potassium bicarbonate	5.5	11
Maize starch	22.5	45
Methylcellulose	0.075	0.15
Sodium laurylsulphate	0.125	0.25
Crospovidone	3	6
Ultramyl	5	10
Coloidal silica	0.55	1.1
Cellulose microcrystalline	0.5	1
Magnesium stearate	1.5	3
Purified water q.s.	100	200
Coating
Opadry OY-35009 red	2	4
Macrogol 400	0.25	0.5

A four-way comparative bioavailability study was carried out on 18 healthy volunteers of both sexes in order to evaluate the in vivo results of the pharmaokinetic profiles of the present formulations if compared to those of bioequivalent fast release formulations such as Cataflam® (25 mg of Diclofenac potassium) and Voltarol® (50 mg of Diclofenac sodium), both by Novartis. The results, which are summarized in FIG. 6, indicate that T_maxis prompter with the present formulations (T1=26 min, T2=24.6 min vs R1=71.4 min and R2=40.8 min) and that C_maxis higher (T1=847 ng/ml and T2=861 ng/ml vs R1=452 ng/ml and R2=703 ng/ml); furthermore, the T_maxof both present formulations shows a coefficient of variation lower than reference formulations (T1=46% and T2=49% vs R1=87% and R2=96%).

EXAMPLE 14

Comparative Test

A further comparative test was carried out on immediate release formulations according to the present invention, containing 50 mg of Diclofenac potassium and 22 mg of potassium bicarbonate, manufactured with different that is, respectively: T1=wet granulation using alcohol, T2=dry granulation by direct compression. The composition in mg of the two formulations is herebelow reported:


Diclofenac potassium	50	50
Potassium bicarbonate	22	22
Mannitol/pearlitol 400 DC	119.9
Mannitol EP cf		50
Maize starch		25
Methocel A4C		0.2
Sodium laurylsulphate	0.1	0.1
Polyplasdone XL	6	1
Ultramyl		2.5
Magnesium stearate	2	4.5
Silicium aerosil		1
Core mass	200	156.3

A comparative bioavailability study was carried out on 6 healthy volunteers of both sexes in order to evaluate the in vivo results of the pharmaokinetic profiles of the present formulations if compared to those of a bioequivalent fast release formulation such Voltaren Rapid® (50 mg of Diclofenac potassium), both by Novartis. The results, which are reported in FIGS. 7-10 are also in this case excellent the T_maxis in fact prompter with the present formulations (T1=18.6 min, T2=16.8 min vs R1=40.8 min) and the C, is higher (T1=1878.3 ng/ml and T2=1744.8 ng/ml vs R1=1307 ng/ml); furthermore, also in this case the T_maxof both present formulations shows a coefficient of variation lower than reference formulation (T1=12.9% and T2=25% vs R1=95.6%).

TABLE 1

Pharmacokinetic parameters for two different diclofenac formulations:
test (Diclofenac potassium salt sachets) and reference
(Diclofenac potassium salt sugar coated tablets)

	t_max	C_max	t_1/2	AUC_0-t
	(h)	(ng/mL)	(h)	(ng · mL⁻¹· h)

Vol. no.	Test	Ref.	Test	Ref.	Test	Ref.	Test	Ref.

Vol. 1	0.250	0.500	1573.000	1186.211	1.505	0.939	1024.511	885.549
Vol. 2	0.250	4.000	2382.368	965.100	0.875	1.358	1653.124	2092.036
Vol. 3	0.184	1.000	2614.655	1352.400	0.796	1.610	1687.529	1763.484
Vol. 4	0.250	3.000	2404.848	735.454	0.996	1.132	1881.944	1834.958
Vol. 5	0.250	0.500	2971.457	1405.000	1.667	1.903	1819.756	1687.075
Vol. 6	0.250	0.750	2158.700	1351.500	0.843	0.650	1197.716	1091.996
Vol. 7	0.250	0.750	1739.200	1741.717	0.596	0.658	1448.713	1301.887
Vol. 8	0.250	0.500	1715.350	534.300	0.818	1.111	991.864	1126.414
Vol. 9	0.250	0.750	444.112	747.800	0.787	1.188	669.084	886.300
Vol. 10	0.267	0.750	2350.100	1110.400	0.960	1.070	1327.808	1020.286
Vol. 11	0.167	0.500	1867.200	1465.502	1.141	0.762	1337.821	892.870
Vol. 12	0.167	0.500	4273.026	1432.200	1.052	0.697	1703.655	1139.003
Vol. 13	0.250	0.500	2097.089	1155.371	1.313	1.198	1486.526	1233.531
Vol. 14	0.167	0.250	2242.684	967.795	0.997	0.837	987.522	927.726
Vol. 15	0.184	0.500	2040.247	1129.957	0.724	0.804	1213.725	1040.424
Vol. 16	0.250	0.750	2143.692	818.200	0.560	1.199	1186.603	1250.221
Vol. 17	0.250	1.500	1527.845	480.900	2.752	1.309	958.821	978.797
Vol. 18	0.250	1.000	1859.608	666.500	1.630	1.383	1131.413	933.008
Vol. 19	0.250	0.750	1537.508	770.100	1.726	1.137	980.348	906.275
Vol. 20	0.250	0.250	1956.004	655.100	0.853	0.883	1309.289	1036.836
Vol. 21	0.250	0.500	3551.360	2421.060	1.322	1.233	2147.217	1639.619
Vol. 22	0.167	0.500	2464.978	1274.648	0.611	0.624	1038.817	816.924
Vol. 23	0.167	0.750	2304.351	453.500	2.066	0.862	1161.414	1049.327
Vol. 24	0.250	0.500	2901.504	894.337	0.970	1.279	1645.384	1086.512
Mean	0.228	0.885	2213.370	1071.461	1.148	1.076	1332.942	1192.544
SD	0.037	0.860	743.099	450.780	0.523	0.320	358.048	350.116
CV %	16.300	97.091	33.573	42.072	45.557	29.700	26.862	29.359
Min.	0.167	0.250	444.112	453.500	0.560	0.624	669.084	816.924
Max.	0.267	4.000	4273.026	2421.060	2.752	1.903	2147.217	2092.036
Geom. Mean	0.225	0.692	2070.719	987.180	1.056	1.032	1287.195	1150.713
Median	0.250	0.625	2151.196	1039.098	0.983	1.122	1261.507	1067.920

	AUC_0-		C_max/AUC_0-	AUC extrapolated
	(ng · mL⁻¹· h)	C₁	(h⁻¹)	(%)

Vol. no.	Test	Ref.	Test	Ref.	Test	Ref.	Test	Ref.

Vol. 1	1050.137	910.868	11.800	18.700	1.498	1.302	2.37	0.00
Vol. 2	1693.172	2092.036	31.700	13.500	1.407	0.461	1.82	1.38
Vol. 3	1718.755	1788.111	27.200	10.600	1.521	0.756	0.83	1.15
Vol. 4	1897.754	1856.346	11.000	13.100	1.267	0.396	1.39	1.88
Vol. 5	1845.486	1719.478	10.700	11.800	1.610	0.817	1.56	1.90
Vol. 6	1216.693	1113.146	15.600	22.500	1.774	1.214	2.50	1.79
Vol. 7	1485.867	1325.661	43.200	25.000	1.170	1.314	1.46	1.78
Vol. 8	1006.522	1146.775	12.400	12.700	1.704	0.466	3.08	2.75
Vol. 9	690.354	911.329	18.700	14.600	0.643	0.821	1.74	1.80
Vol. 10	1351.357	1038.971	17.000	12.100	1.739	1.069	3.01	3.01
Vol. 11	1379.311	920.579	25.200	25.200	1.354	1.592	1.62	2.03
Vol. 12	1731.709	1162.638	18.500	23.500	2.468	1.232	1.26	1.56
Vol. 13	1505.454	1253.088	10.000	11.300	1.393	0.922	2.58	2.26
Vol. 14	1013.665	949.163	18.200	17.700	2.212	1.020	1.91	2.86
Vol. 15	1237.399	1071.029	22.700	26.400	1.649	1.055	1.33	1.58
Vol. 16	1202.653	1270.280	19.900	11.600	1.782	0.644	4.16	2.80
Vol. 17	1000.433	1006.986	10.500	14.900	1.527	0.478	5.51	2.26
Vol. 18	1197.411	954.597	28.100	10.800	1.553	0.698	2.57	2.11
Vol. 19	1006.229	925.835	10.400	11.900	1.528	0.832	2.03	2.02
Vol. 20	1336.472	1058.242	22.400	16.800	1.464	0.619	1.19	1.07
Vol. 21	2173.030	1657.372	13.500	10.000	1.634	1.461	1.75	1.68
Vol. 22	1057.293	830.908	21.000	15.500	2.331	1.534	3.13	1.80
Vol. 23	1198.950	1068.588	12.600	15.500	1.922	0.424	2.19	1.94
Vol. 24	1682.290	1108.024	26.400	11.700	1.725	0.807	2.10	1.78
Mean	1361.600	1214.169	19.113	15.725	1.620	0.914	2.213	1.883
SD	358.359	348.108	8.244	5.160	0.377	0.365	1.035	0.641
CV %	26.319	28.671	43.134	32.812	23.277	39.991	46.795	34.056
Min.	690.354	830.908	10.000	10.000	0.643	0.396	0.833	0.000
Max.	2173.030	2092.036	43.200	26.400	2.468	1.592	5.512	3.010
Geom. Mean	1316.580	1173.325	17.609	15.011	1.573	0.841	2.023	//
Median	1286.936	1089.527	18.350	14.050	1.582	0.827	1.974	1.843

indicates data missing or illegible when filed

Claims

1) A fast-release diclofenac composition, in the form of a unit dose packet of powder for dissolving or suspending in water, or in the form of a fast release layer in a two layered diclofenac tablet that comprises a fast layer and a slow layer, wherein said composition comprises diclofenac in acid and/or salt form.

2) The composition of claim 1 wherein said diclofenac is present as diclofenac potassium.

3) The composition of claim 1 wherein said diclofenac is present in an amount ranging from about 10 to about 60 mg.

4) The composition of claim 1 in the form of a unit dose packet of powder wherein said diclofenac is present in an amount of about 50 mg.

5) The composition of claim 1 in the form of a unit dose packet of powder wherein said diclofenac is present as diclofenac potassium in an amount of about 50 mg.

6) The composition of claim 1 in the form of a unit dose packet of powder, wherein said composition is capable of yielding an average T_maxof diclofenac in a human patient between 5 and 30 minutes after administration of said diclofenac to said patient, said average T_maxhaving a coefficient of variation (CV %) less than about 70%.

7) The composition of claim 1 in the form of a unit dose packet of powder, wherein said composition is capable of yielding an average T_maxof diclofenac in a human patient between 13 and 27 minutes after administration of said diclofenac to said patient, said average T_maxhaving a coefficient of variation (CV%) less than about 70%.

8) The composition of claim 1 in the form of a fast release layer in a two layered diclofenac tablet.

9) The composition of claim 1 in the form of a fast release layer, wherein said composition comprises about 15 mg, of diclofenac potassium salt, and said slow release layer comprises about 70 mg, of diclofenac potassium salt.

10) The composition of claim 1, further comprising means for potentiating the bioavailability of said diclofenac.

11) The composition of claim 10 wherein said means decreases the Tmax of said diclofenac.

12) The composition of claim 10 wherein said means increases the Cmax of said diclofenac.

13) The composition of claim 10 wherein said means decreases the coefficient of variation of the Cmax of said diclofenac.

14) The composition of claim 10 in the form of a unit dose packet of powder wherein said diclofenac is present in an amount of from about 10 to about 60 mg.

15) The composition of claim 10 in the form of a unit dose packet of powder wherein said diclofenac is present in an amount of about 50 mg.

16) The composition of claim 10 wherein said means comprises one or more alkali metal carbonates or bicarbonates.

17) The composition of claim 10 wherein said means comprises one or more alkali metal carbonates or bicarbonates in an amount greater than about 20 wt. % based on the weight of said diclofenac.

18) The composition of claim 10 in the form of a unit dose packet of powder wherein said diclofenac is present in an amount of about 50 mg, and said means comprises one or more alkali metal carbonates or bicarbonates in an amount greater than about 20% based on the weight of said diclofenac.

19) The composition of claim 10 in the form of a unit dose packet of powder wherein said diclofenac is present as diclofenac potassium in an amount of about 50 mg, and said means comprises potassium bicarbonate in an amount greater than about 20% based on the weight of said diclofenac.

20) The composition of claim 10 in the form of a unit dose packet of powder wherein said diclofenac is present as diclofenac potassium in an amount of about 50 mg, and said means comprises potassium bicarbonate in an amount of from about 40 wt. % to about 80 wt. % based on the weight of said diclofenac.

21) A fast-release diclofenac composition, in the form of a unit dose packet of powder for dissolving or suspending in water, or in the form of a fast release layer in a two layered diclofenac tablet comprising a fast layer and a slow layer, wherein the composition comprises diclofenac in acid and/or salt form and means for potentiating the bioavailability of said diclofenac.

22) The composition of claim 21 wherein said means comprises greater than about 20 wt. % of one or more alkali metal carbonates or bicarbonates based on the weight of said diclofenac.

23) A fast-releasing diclofenac composition, in the form of a unit dose packet of powder for dissolving or suspending in water, comprising about 50 mg, of diclofenac in acid and/or salt form.

24) The composition of claim 23 wherein said diclofenac is present as diclofenac potassium.

25) The composition of claim 23 wherein said diclofenac is present as diclofenac potassium, further comprising from about 40 to about 80 wt. % of potassium bicarbonate.

26) A fast-release diclofenac composition, in the form of a fast release layer in a two layered diclofenac tablet comprising a fast layer and a slow layer, comprising from about 10 to about 60 mg, of diclofenac in acid and/or salt form.

27) The composition of claim 26 wherein said diclofenac is present as diclofenac potassium.